The U.S. Food and Drug Administration has given Medtronic (NYSE:MDT) the go-ahead on a clinical trial to test its next generation of MRI pacemaker technology, the Minnesota company announced Monday.
Medtronic Inc. said Monday that the Food and Drug Administration approved its application to conduct a clinical trial in the United States evaluating a new pacemaker that is compatible with MRI scans.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results